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10 Abstract
11 Background There is a growing interest in policy making
12 for using utility measures and identifying algorithms to
13 convert disease-specific measures into utilities.
14 Objectives To analyse the relationship between EQ-5D,
15 Dermatology Life Quality Index (DLQI) and Psoriasis
16 Area and Severity Index (PASI) in psoriasis. To transform
17 DLQI scores, and key clinical, demographic and health
18 service utilisation variables into utilities.
19 Methods A cross-sectional questionnaire survey of 200
20 consecutive adult patients with moderate to severe psoria-
21 sis was carried out in two Hungarian university clinics. The
22 relationship between the outcome measures were analysed
23 with correlations and with the known-groups method.
24 Bivariate and multivariate regression algorithms on EQ-5D
25 scores were formulated.
26Results The mean age of respondents was 51 years
27(SD = 12.9), 68.5 % were male, and 51.5 % received
28biological therapy. Median EQ-5D, DLQI, and PASI scores
29were 0.73, 3.0, and 3.45, respectively. EQ-5D showed a
30moderate correlation with the DLQI and with the PASI
31(rs = -0.48 and -0.43, p \ 0.05). Strong correlation was
32found between DLQI and PASI (rs = 0.81, p \ 0.05).
33DLQI and PASI discriminated better among groups cate-
34gorised by the localisation of the lesions than EQ-5D.
35Presence of psoriasis on the neck and/or de´colletage was
36associated with the greatest health related quality of life
37(HRQOL) impairment. Ten variables were incorporated in
38a multivariate algorithm that accounted for 48.8 % of EQ-
395D variance (ANOVA p \ 0.001).
40Conclusions This study provided the first evidence that
41patients with visible psoriatic lesions have significantly
42worse HRQOL compared to those with non-visible lesions,
43measured not only with DLQI but also with EQ-5D. In
44addition to demographic and clinical variables, our model
45included health service utilisation variables related to
46psoriasis, and explained higher proportion of EQ-5D vari-
47ance than any previous findings in the literature. 8
49Keywords Psoriasis  Quality of life  EQ-5D  DLQI 
50Mapping
51JEL Classification I19
52Introduction
53Psoriasis is a chronic immune-mediated inflammatory
54disease of the skin with various presentations and clinical
55courses. It is estimated to affect approximately 0.73–2.9 %
56of the population throughout Europe [1]. Extra-cutaneous
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57 manifestations such as arthritis, cardiovascular diseases or
58 mental disorders are often associated with psoriasis [1]. To
59 date, there is no definitive cure for the disease, and,
60 therefore, patients usually need long-term treatment.
61 Severe psoriasis has a profound impact on patients’ health
62 related quality of life (HRQOL) encompassing physical,
63 psychological, and socio-economic levels [2].
64 Economic evaluations require data on HRQOL on
65 preference-based measures that capture preference weights
66 (called a utility, in terms of desirability) about values of
67 different health states. Also, in many countries utility
68 measures are required for reimbursement decisions. EQ-5D
69 is the most commonly used utility measure in health eco-
70 nomic analyses, however, it is rarely administered in
71 clinical trials. Therefore, there is a demand for cross-
72 walking (or mapping) algorithms to estimate EQ-5D utility
73 scores from other HRQOL measures.
74 In recent years, introduction of biological agents
75 (adalimumab, etanercept, infliximab, and ustekinumab)
76 opened up new horizons in the treatment of patients
77 with severe psoriasis. Compared to standard treatment,
78 they proved clinical efficacy, but their use is associated
79 with much higher costs and societal burden as well
80 [3, 4]. Due to biologicals, HRQOL measures should be
81 able to face a new patient population with better health
82 state, with currently unexplored possible predictors
83 of HRQOL and with new expectations of treatment
84 outcomes.
85 There have been continuous discussions concerning the
86 most appropriate, valid, sensitive, and reliable HRQOL
87 assessment tool in psoriasis [5]. Dermatology Life Quality
88 Index (DLQI), Psoriasis Area and Severity Index (PASI), and
89 Short Form-36 (SF-36) are the most widely used instruments
90 in psoriasis. Although these are focusing on different aspects
91 of HRQOL, several overlaps exist between them.
92 DLQI was the first disease-specific questionnaire in
93 dermatology with 20 years of use in clinical trials and in
94 everyday clinical practice by now. It has been considered
95 a simple, valid, and reliable outcome measure is psoriasis
96 [6]. Nevertheless, from the perspective of health eco-
97 nomics, a major disadvantage of DLQI has to be
98 addressed. Due to it is not a preference-based measure, it
99 does not enable one to calculate utilities for economic
100 evaluations.
101 Over the past decade, the literature on mapping the
102 general measure EQ-5D in different diseases has rapidly
103 grown. According to the University of Oxford HERC
104 online database of mapping studies [7], only two papers
105 and a conference abstract have been published about
106 mapping EQ-5D in psoriasis, so far [8–10]. All these
107 researches investigated the relationship between the der-
108 matology-specific DLQI questionnaire and the EQ-5D
109 index.
110Recent evidences suggest a significant moderate corre-
111lation between EQ-5D and DLQI global scores [8, 11].
112Prior mapping studies could explain only 27–31.3 % of the
113variance of EQ-5D [8–10]. Consequently, almost 70 % of
114the possible predictors of EQ-5D in psoriasis has still
115remained hidden.
116The objectives of this present cross-sectional study
117are, at first, to analyse correlations between the widely
118used HRQOL and disease severity instruments of psori-
119asis and compare their capacity to distinguish among
120patients’ severity groups; secondly, to seek for new
121possible predictors of HRQOL to establish mapping
122models on EQ-5D score and on the visual analogue scale
123(EQ VAS).
124Methods
125Patients
126Between September 2012 and May 2013, a cross-sec-
127tional questionnaire survey of consecutive adult psoriasis
128patients from two Hungarian university clinics was car-
129ried out. The number of participants was limited to
130approximately 100 patients from each clinic. Patients
131included were required to be 18 years or older and to
132have been diagnosed with moderate to severe psoriasis
133(PASI [10 or DLQI [10 or patient using systemic or
134biological treatment) 12 months or more before the
135inclusion to the study. Data were collected by derma-
136tologists at Semmelweis University, Department of Der-
137matology, Venereology and Dermatooncology (Budapest)
138and at the University of Debrecen, Clinic of Dermatol-
139ogy. All patients were invited to participate by their
140physicians during outpatient visits and signed an
141informed consent form. The study was approved by the
142national research ethic committee (ETT-TUKEB
14335183/2012-EKU).
144Outcome measures and assessment
145All participants and their physicians were asked to com-
146plete a self-designed questionnaire. Patients’ question-
147naires concerned demographic data, general health state,
148quality of life (EQ-5D, EQ VAS, DLQI, self-assessed
149disease severity VAS) affected body sites, and disease
150duration. Dermatologists’ questionnaires were based on the
151patients’ clinical type of psoriasis, PASI, psoriasis treat-
152ments in the last 12 months, current clinical outcomes, and
153physician’s’ global assessment of disease activity visual
154analogue scale (PGA VAS).
155Quality of life was captured by the validated Hungarian
156versions of EQ-5D questionnaire, by PGA VAS and by
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157 disease-specific DLQI. Clinical severity of psoriasis
158 was assessed by using Psoriasis Area and Severity Index
159 (PASI-72) and patients’ self-assessed disease severity
160 VAS. Questions included if there were any GP visit(s) in
161 the last months, dermatologist visit(s) in the last three -
162 months and hospitalisation(s) in the last 12 months.
163 Necessity of home help (professional or informal, e.g.,
164 family members) in the last one month and work impair-
165 ment due to psoriasis were also recorded.
166 EQ-5D consists of a five-item instrument to assess
167 general HRQOL (mobility, self-care, usual activities, pain/
168 discomfort, and anxiety/depression), and of a visual ana-
169 logue scale (EQ VAS). In the current survey, EQ-5D-3L
170 version was used in which each dimension has three
171 response levels (no problems, some problems, and severe
172 problems), accordingly, 35 = 243 combinations of health
173 states are possible. Due to lack of evaluated Hungarian
174 tariffs, the UK weights were applied to calculate global
175 EQ-5D scores; thus, utility outcomes can range from -0.59
176 to ?1, where -0.59 is corresponding to the worst and ?1
177 corresponding to the best possible quality of life [12]. EQ
178 VAS is a 20 cm long, vertical visual analogue scale with
179 endpoints of ‘0’ (worst possible health state) and ‘100’
180 (best possible health state) recording patients’ self-rating of
181 their overall health, which as well enables determining
182 utilities.
183 DLQI is a disease-specific self-assessment questionnaire
184 validated for measuring HRQOL in psoriasis [13, 14]. The
185 ten-item questionnaire’s scale ranged from ‘0’ to ‘30’,
186 where higher scores indicate greater disability experienced
187 by patients. Each questions of DLQI scores quality of life
188 impairment due to the dermatologic condition in a 4-point
189 Likert scale, including aspects such as symptoms, side
190 effects of treatment, daily activities, work or school, per-
191 sonal relationships, leisure activities, and feelings of
192 embarrassment.
193 PASI-72 (hereinafter PASI) is a quantitative rating scale
194 for psoriasis based on the severity of the lesions and the
195 size of psoriatic areas assessed by physicians. It is widely
196 used both in clinical trials to measure clinical effectiveness
197 and in routine care to evaluate treatment success. To cal-
198 culate PASI scores, the body is divided into four sec-
199 tions based on the estimated area of the skin affected
200 (head = 0.1, upper extremities = 0.2, trunk = 0.3 and
201 lower extremities = 0.4). Each area is graded by itself
202 from 0 to 6, depending on the estimated percentage of the
203 psoriatic involvement (0 = 0 %, 1 B 10 %, 2 = 10–29 %,
204 3 = 30–49 %, 4 = 50–69 %, 5 = 70–89 %, and
205 6 = 90–100 %). Within each area, severity is judged by
206 the presence of three clinical signs: erythema, induration,
207 and desquamation (measured on a scale of 0–4). Total
208 PASI values range from 0 to 72, with higher scores indi-
209 cating greater disease severity.
210Statistical analysis
211Spearman’s rank correlation was used to test associations
212between outcome measures.
213Mann–Whitney U test was performed to compare the
214differences in the distribution of EQ-5D, DLQI, and PASI.
215The known-groups method was applied to compare the
216outcome measures ability to detect differences between
217groups with known attributes. Overall 11 categories,
218including clinical types, localisation and several medical
219records were selected for grouping variables. In each cat-
220egory we expected that patients responded ‘Yes’ to a
221question had worse scores in quality of life or in disease
222severity measures than those who responded ‘No’ (i.e.,
223control group). To compare the means of the two groups,
224effect size (Cohen’s d) was calculated by dividing the
225difference of the means by pooled standard deviation. The
226Cohen’s d is considered small if 0.2–0.5, medium if
2270.5–0.8, or large if [0.8, respectively, where the measure
228with a higher value can better distinguish between groups
229[15].
230To determine possible predictors of quality of life in
231psoriasis, age, disease duration, body mass index (BMI),
232and instruments that significantly correlated with EQ-5D,
233were enrolled as continuous variables. Additionally, those
234categorical variables were selected as possible predictors
235which proved a significant EQ-5D difference between their
236two possible outcomes (e.g., presence or absence of a
237clinical type, symptom or treatment). From this point for-
238ward, negative EQ-5D values were truncated to 0. In a
239bivariate mapping model on EQ-5D score and on EQ VAS,
240only DLQI was included as an independent predictor of the
241target variables. Then, to find an optimal algorithm in a
242multivariate approach that can explain the highest pro-
243portion of variance, we included all the possible predictors,
244which were found to be in a significant relationship with
245the target variable.
246Data were analysed using SPSS version 20.0 (SPSS Inc.,
247Chicago, IL, USA). All the applied statistics were two-
248sided with a significance level of p \ 0.05.
249Results
250Patient characteristics
251Altogether 200 patients participated in the survey. Patient
252characteristics are described in Table 1.
253The mean age was 51 years with male predominance
254(68.5 %). The mean disease duration was 22 years. Overall
255159 (79.4 %) of the participants were overweight
256(BMI C 25). The most frequent type of psoriasis was
257chronic plaque psoriasis with 126 (63 %), followed by nail
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258 psoriasis 71 (35.5 %), scalp psoriasis 69 (34.5 %), psoriatic
259 arthritis 57 (28.5 %), inverse psoriasis 18 (9 %), pal-
260 moplantar psoriasis 12 (6 %), erythrodermic psoriasis four
261 (2 %), and guttate psoriasis two (2 %) (combinations are
262 possible). In total, 50 (25 %) of the patients reported pso-
263 riasis involvement of the face, 36 (18 %) of the neck and/or
264 de´colletage, 83 (41.5 %) of the hands and/or palms, 69
265 (34.5 %) of the hand nails, 110 (55 %) of the forearms, and
266 134 (67 %) of the lower extremity, respectively. At the
267 time of the survey, 59 (29.5 %) of the patients had no
268 symptoms at all (i.e., PASI = 0).
269 Among the included patients, 103 (51.5 %) received
270 biological drug in monotherapy or combination therapy, 61
271 (30.5 %) systemic non-biological therapy, and 30 (15 %)
272 only topical treatment at the time of the survey.
273 The distribution of scores in the applied quality of life
274 instruments were skewed, thus, the median is considered a
275 better measure for the centre. The medians of quality of life
276 tools were 0.73 for EQ-5D, 70 for EQ VAS, 3 for DLQI
277 global score and 3.45 for PASI, respectively.
278 Frequencies of health service utilisation variables,
279 including medical examinations, types of treatment, and
280 additional non-reimbursed services are described elsewhere
281 [16].
282 Comparison
283 Results obtained from correlation analysis of the instru-
284 ments are demonstrated in Table 2. EQ-5D score showed a
285 moderate negative correlation with DLQI, PASI, PGA, and
286 with patients self-assessed disease severity VAS
287 (0.29 \ Spearman’s-rho \ 0.5). A strong significant cor-
288 relations were found among DLQI, PASI, PGA, and self-
289 assessed disease severity VAS.
290The differences between known-groups are presented in
291Table 3. As expected, in each category patients with more
292severe disease (responded ‘Yes’) reported significantly
293worse quality of life than the control group (Mann–Whit-
294ney U test, p \ 0.05). EQ-5D revealed the highest effect
295sizes in 4 out of the 11 examined categories: GP visit(s) in
296the last month, necessity of home help in the last month,
297and in the clinical types of palmoplantar psoriasis and
298psoriatic arthritis. Nevertheless, it was the least effective
299tool in capturing the variables of hospitalisation(s) in the
300last year, biological therapy and the localisations of pso-
301riatic lesions. DLQI and PASI were able to discriminate
302between these groups better. Patients with visible lesions
303(on body areas uncovered by clothes—face, neck, de´col-
304letage, hands, palms, hand nails) reported poorer HRQOL
305than those without visible lesions measured with any
306instrument.
307Mapping EQ-5D
308A simple linear regression of DLQI onto both EQ-5D score
309and EQ VAS was performed: EQ-5D = 0.8 - 0.02*DLQI
310(adjusted r2 = 0.169, ANOVA p \ 0.001), EQ VAS =
31171.23 - 1.07*DLQI (adjusted r2 = 0.129, ANOVA
312p \ 0.001). Thus, DLQI global score explained 16.9 % of
313the variance of EQ-5D and 12.9 % of the variance of EQ
314VAS.
315In order to establish a multivariate function, only those
316variables were applied which were previously tested and
317showed significant correlation (continuous variables) or
318significant EQ-5D difference among their outcomes (cate-
319gorical variables) with the target indices. Thus, overall, 23
320possible predictors of EQ-5D and 21 of EQ VAS were
321identified.
322In the final stepwise multiple regression, ten out of the
32323 possible predictors of EQ-5D and six out of the 21
324possible predictors of EQ VAS were enrolled (see
325Table 4). The models are explaining 48.8 % of EQ-5D
Table 1 Patient characteristics
n Mean SD Median Range
Age (years) 200 51.24 12.9 53 21–85
Psoriasis duration
(years)
200 21.96 11.67 20.5 1–63
BMI (kg/m2) 199 29.89 5.44 29.41 16.45–46.81
EQ-5D score (–0.594
to 1)
192 0.69 0.31 0.73 -0.43 to 1
EQ VAS (0–100) 196 64.43 21.34 70.00 0–100
DLQI (0–30) 194 6.29 7.29 3.00 0–28
PASI (0–72) 200 8.01 10.01 3.45 0–49.5
Physician’s global
assessment VAS
(0–100 mm)
189 23.39 28.24 7.00 0–100
Self-assessed disease
severity VAS
(0–100 mm)
199 34.84 33.33 20.00 0–100
Table 2 Spearman’s correlations between the outcome measures
EQ-5D score
(-0.59 to 1)
DLQI PASI PGA
VAS
EQ VAS (0–100) 0.56* -0.43* -0.42* -0.42*
DLQI (0–30) -0.48* – 0.81* 0.80*
PASI (0–72) -0.43* 0.81* – 0.92*
PGA VAS (0–100 mm) -0.42* 0.80* 0.92* –
Self-assessed disease
severity VAS
(0–100 mm)
-0.41* 0.78* 0.78* 0.79*
* Significant p \ 0.05. For DLQI and PASI ‘0’ and for all other
measures, the highest value is the best possible outcome
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326 variance and 30.4 % of EQ VAS variance (adjusted
327 R2 = 0.488 and 0.304, ANOVA p \ 0.001). Consequently,
328 mapping functions of the two indices are more accurate
329 than they there were in our bivariate regressions. Three
330 predictors were included in both target variables’ model,
331 hospitalisation(s) in the last 12 months, the GP visit(s) in
332 the last month, and presence of palmoplantar involvement.
333Furthermore, we noted that global DLQI score did not have
334an impact on EQ VAS values. However, we found that
335patients’ self-assessed disease severity is implied in the
336multiple model of EQ VAS with an unstandardized
337regression coefficient (b) of -0.14. Hence, 1 point fall on
338the patients’ self-assessed VAS eventuates 0.14 point fall
339in EQ VAS.
Table 3 Differences in effect size (Cohen’s d) between outcome measures with the known-groups method
EQ-5D** EQ-5D VAS DLQI PASI
n Mean Effect
size
n Mean Effect
size
n Mean Effect
size
n Mean Effect
size
Clinical type of psoriasis
Palmoplantar psoriasis
No 152 0.71 (0.29) 1.2 162 63.59 (21.08) 0.63 160 6.41 (7.37) 0.69 162 8.03 (9.47) 1.04
Yes 12 0.36 (0.39)* 12 50.33 (21.42)* 12 11.42 (6.82)* 12 18.38 (16.04)*
Psoriatic arthritis
No 118 0.77 (0.24) 1.03 121 65.61 (20.7) 0.44 119 5.57 (6.98) 0.51 121 6.95 (9.12) 0.55
Yes 56 0.48 (0.36)* 57 56.61 (20.76)* 57 9.26 (7.70)* 57 12.42 (11.47)*
Localisation of psoriasis
Visible lesions (on body areas uncovered by clothes)
No 71 0.79 (0.24) 0.54 72 72.1 (19.77) 0.6 72 1.49 (3.98) 1.25 74 2.26 (5.24) 1.02
Yes 113 0.63 (0.33)* 116 59.75 (21.23)* 114 9.3 (7.36)* 118 11.34 (10.61)*
Facial involvement
No 144 0.74 (0.28) 0.55 147 66.82 (20.73) 0.46 145 4.63 (6.48) 0.98 150 5.65 (8.0) 1.04
Yes 48 0.57 (0.37)* 49 57.23 (21.75)* 49 11.2 (7.38)* 50 15.1 (12.01)*
Neck and/or de´colletage involvement
No 156 0.74 (0.28) 0.89 160 67.75 (20.26) 0.9 158 4.47 (6.28) 1.59 164 5.37 (7.63) 1.77
Yes 36 0.48 (0.34)* 36 49.65 (19.97)* 36 14.28 (5.95)* 36 20.01 (10.89)*
Psoriasis on hands and/or palms
No 111 0.75 (0.26) 0.46 114 68.41 (20.08) 0.46 113 3.96 (6.38) 0.83 117 4.61 (7.24) 0.9
Yes 81 0.61 (0.35)* 82 58.88 (21.92)* 81 9.53 (7.27)* 83 12.8 (11.38)*
Psoriasis on hand nails
No 127 0.74 (0.28) 0.46 128 67.06 (21.76) 0.36 128 4.58 (6.7) 0.73 131 6.19 (9.52) 0.55
Yes 65 0.60 (0.35)* 68 59.47 (19.76)* 66 9.61 (7.29)* 69 11.47 (10.09)*
Medical history
GP visit(s) in the last month due to psoriasis
No 145 0.77 (0.27) 1.05 148 68.46 (20.05) 0.82 146 4.67 (6.37) 0.98 151 6.52 (9.33) 0.63
Yes 47 0.47 (0.32)* 48 51.99 (20.58)* 48 11.21 (7.76)* 49 12.59 (10.74)*
Hospitalisation(s) in the last 12 months due to psoriasis
No 138 0.74 (0.28) 0.5 140 68.82 (19.52) 0.76 138 4.76 (6.36) 0.77 143 6.58 (9.83) 0.52
Yes 54 0.59 (0.36)* 56 53.44 (21.91)* 56 10.05 (8.08)* 57 11.61 (9.64)*
Use of home help (professional or informal) in the last month
No 165 0.75 (0.25) 1.45 169 66.31 (20.78) 0.66 167 5.09 (6.66) 1.3 173 6.49 (8.69) 1.22
Yes 27 0.35 (0.41)* 27 52.65 (21.43)* 27 13.7 (6.70)* 27 17.77 (12.40)*
Biological therapy
No 90 0.63 (0.31) 0.37 93 57.46 (18.35) 0.66 93 10.8 (7.4) 1.48 97 13.87 (10.72) 1.39
Yes 102 0.75 (0.31)* 103 70.72 (21.96)* 101 2.14 (3.92)* 103 2.5 (4.91)*
* Significant (p \ 0.05) in Mann–Whitney U test; ** Minimum important difference: 0.09 EQ-5D index score, Shikiar et al. [31]
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340 Discussion
341 In this present study, our first purpose was to analyse
342 correlations between quality of life and disease severity
343 measures, and compare their ability in detecting differ-
344 ences between known groups in a sample of 200 moderate
345 to severe psoriasis patients of two Hungarian university
346 clinics.
347 As a result of the correlation analysis, we found the
348 expected significant correlations between EQ-5D, DLQI,
349 PASI, PGA, and self-assessed disease severity VAS. All
350 the included outcomes correlated only moderately with
351 EQ-5D (rs = 0.41–0.48, p \ 0.05). DLQI global score
352 correlated stronger with PASI, PGA, and with self-assessed
353 disease severity, than with EQ-5D.
354 To date, there are only a few cross-sectional studies in
355 the literature reporting correlation results on outcomes
356 measures in psoriasis. Similarly to our results, Norlin et al.
357 [8] in a sample of 2,450 patients across Sweden found
358 EQ-5D and DLQI moderately correlated (rs = -0.55,
359 p \ 0.001). This is further supported by a survey including
360 273 patients from Finland where authors observed mod-
361 erate correlation between EQ-5D and DLQI (r = -0.52,
362 p \ 0.001) [11]. Hjortsberg et al. also pointed out that
363 DLQI score was more highly correlated with patients’ self-
364 assessed disease severity than with the EQ-5D (r = 0.71,
365 p \ 0.001), likewise in our study (rs = 0.8, p \ 0.05).
366Two observational studies reported a weak correlation
367between PASI and EQ-5D (r = -0.17, -0.25) [8, 9]. In
368contrast, we noted moderate correlation (r = -0.43)
369between these two measures. It is, therefore, likely that
370different clinical protocols of the countries and different
371patient characteristics of the samples (e.g., psoriasis
372severity, rate of biological treatment) account for the
373imparity.
374Despite prior evidences that found significant moderate
375correlations (r = 0.51, 0.54) between PASI and DLQI, we
376observed strong correlation (rs = 0.81) between these two
377instruments [8, 17]. We assume that major reasons for the
378differences are the distinctions amongst the types of
379treatment (e.g., the proportion of patients on biologicals)
380and psoriasis severity of the patients included. This
381assumption is confirmed by the evidence that we demon-
382strated stronger correlation between DLQI and PASI scores
383amongst the patients treated with biologicals (rs = 0.76 vs
3840.53, p \ 0.001). Furthermore, possible difficulties were
385described in the comparison of DLQI records related to the
386patients’ different cultural backgrounds. Findings of Nij-
387sten et al. [18] suggest that patients from different countries
388respond differently to a substantial proportion of DLQI
389items, although they have the same HRQOL impairment.
390A recently conducted systematic review examined the
391correlation between DLQI and PASI throughout clinical
392trials of biological agents [19]. Based on 13 randomised
Table 4 Regression coefficients in the multivariate mapping on EQ-5D and EQ-5D VAS
EQ-5D score EQ VAS
Unstandardized
regression coefficient
(b)
Standardized
regression
coefficient
p Unstandardized
regression coefficient
(b)
Standardized
regression
coefficient
p
Constant 1.026 \0.001 110.588 \0.001
Age – – – -0.350 -0.214 0.002
Gender (female) -0.090 -0.145 0.014 – – –
BMI – – – -0.600 -0.157 0.025
Psoriasis duration -0.004 -0.169 0.006 – – –
DLQI -0.080 -0.190 0.023 – – –
Self-assessed disease severity
VAS
– – – -0.14 -0.218 0.004
Chronic plaque psoriasis -0.089 -0.151 0.029 – – –
Palmoplantar psoriasis -0.347 -0.269 \0.001 -12.570 -0.145 0.034
Scalp psoriasis 0.152 0.252 0.001 – – –
Psoriatic arthritis -0.134 -0.212 0.002 – – –
GP visit(s) due to psoriasis in the
last month
-0.160 -0.227 \0.001 -8.112 -0.167 0.022
Hospitalisation(s) due to
psoriasis in the last 12 months
-0.104 -0.160 0.013 -12.075 -0.253 \0.001
Use of home help (professional
or informal) in the last month
-0.139 -0.160 0.021 – – –
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393 controlled trials (RCT), the proportion of PASI improve-
394 ment revealed a strong correlation (r = 0.8) with DLQI
395 from the baseline to the 10–16 weeks of treatment, con-
396 firming our findings, where more than half of the enrolled
397 patients received biological therapy.
398 In our study, the highest correlation (rs = 0.92,
399 p \ 0.05) was observed between PASI and PGA VAS.
400 Both measures are commonly used in clinical trials. Our
401 finding is consistent with a review based on 30 biological
402 RCTs [20]. According to the results of Robinson et al. [20]
403 the two outcome tools, PGA 0,1 and PASI 75 were cor-
404 related very closely (r = 0.9157 for study weeks 8–16;
405 r = 0.892 for weeks 17–24, and r = 0.9559 for longer than
406 24 weeks, p \ 0.01).
407 In the comparison of outcome measures with the known-
408 groups method, 11 aspects of psoriasis severity were
409 involved, including clinical types, localisations, and health
410 service utilisation variables. A similar method was applied
411 by Revicki et al. [21] validating the psoriasis symptom
412 inventory (PSI), by Dauden et al. [22] validating the PSO-
413 LIFE questionnaire, and by Brodszky et al. [23] assessing the
414 Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire
415 and the Health Assessment Questionnaire (HAQ) in psoriatic
416 arthritis. Each of the evaluated tools (see Table 3) was found
417 to be an effective instrument, which was able to discriminate
418 between these groups regarding the severity of psoriasis.
419 Merely a modest effect size was found within the group of
420 hospitalisation(s), similarly to prior results of a study con-
421 ducted by Brodszky et al. [23] with the same method in
422 psoriatic arthritis, also in Hungary.
423 The effectiveness of the four assessed tools in tackling
424 QOL varies in different segments. EQ-5D was found
425 remarkably effective from the viewpoint of general
426 HRQOL grouping variables such as the necessity of home
427 help, since the ability for self-care is one of the dimensions
428 of the EQ-5D index. Focusing on strengths of the disease-
429 specific measures, the discriminating power of DLQI
430 proved the greatest or the second greatest in nine out of the
431 11 implied categories. In addition, DLQI scores correlated
432 stronger with PASI, patients’ self-assessed disease severity
433 and with PGA as well than EQ-5D. Therefore, DLQI is an
434 optimal choice to measure general HRQOL and skin-rela-
435 ted symptoms assembled. Not surprisingly, PASI was
436 found especially effective in the distinction of the aspects
437 of visible lesions, localisation of psoriasis, palmoplantar
438 involvement, and biological therapy, because these vari-
439 ables are directly related to disease severity. The presence
440 of visible lesions was analysed with the same method, but
441 with a different instrument (PSO-LIFE) by Daude´n et al.
442 [24]. Similarly to our findings, the authors suggest that
443 HRQOL impairment perceived by patients with visible
444 lesions is greater than the effect reported by patients with
445 less visible lesions [24].
446Furthermore, we assessed HRQOL in patients with the
447presence or lack of lesions on certain body regions. The
448neck and/or de´colletage involvement was associated with
449the greatest EQ-5D reduction, followed by the forearm, and
450facial lesions. Also, the neck and/or de´colletage involve-
451ment proved the highest effect size in DLQI scores, fol-
452lowed by the forearm, and the leg and/or shin lesions.
453Unexpectedly, the effect sizes of the facial psoriasis, which
454is likely the most bothersome localisation due to stigmat-
455isation and cosmetic issues, were overtaken by the neck
456and/or de´colletage measured by any examined outcome.
457We assume that this is due to the fact that in our sample the
458majority of the patients with neck and/or de´colletage
459involvement (n = 36) had lesions on two or more body
460sites, covering a higher proportion of their entire body
461surface.
462Our second aim was to investigate new possible pre-
463dictors of EQ-5D score and EQ VAS, and seek for a
464mapping algorithm for these variables. Bivariate analysis
465on EQ-5D was previously published in two studies. A
466simple linear regression developed by Currie and Conway
467[10] amongst 94 patients could account for 27 % of EQ-5D
468variance: EQ-5D = 0.956 - 0.02548*DLQI. The model
469of Norlin et al. [8] was able to explain 28 % of the EQ-5D
470variance (EQ-5D = 0.8777 - 0.0196*DLQI). Our model
471is in line with these two bivariate algorithms, the constant
472term is about 0.8 and one point increase in DLQI is
473expected to result in a reduction of 0.02 point in EQ-5D.
474A study from Germany including 1,511 patients per-
475formed by Blome et al. [9] could predict 24.2 % of the
476variability of EQ VAS with the following mapping algo-
477rithm: EQ VAS = 77.367 - 1.493*DLQI (p \ 0.001).
478Furthermore, these results were cross-validated by a data-
479base of 2,009 patients.
480To develop our multivariate function, we explored ten
481variables as possible predictors of EQ-5D: DLQI, gender,
482psoriasis duration, palmoplantar involvement, psoriatic
483arthritis, chronic plaque psoriasis, scalp psoriasis, necessity
484of home help in the last month, GP visit(s) due to psoriasis
485in the last month, and hospitalisation(s) due to psoriasis in
486the last 12 months. The clinical type of palmoplantar
487involvement had the greatest negative standardized
488regression coefficient. This finding seems to be consistent
489with earlier researches, which described that patients with
490palmoplantar involvement have reported significantly
491greater physical disability, discomfort, and work or leisure
492impairment than those without palmoplantar involvement
493[25, 26]. In contrast, scalp psoriasis was the only variable
494with positive unstandardized regression coefficient (b)
495involved in the model. This might be conceivably due to
496the high proportion of the less severe cases amongst the
497patients of our sample with scalp involvement (n = 69),
498and, therefore, this finding cannot be generalised.
Exploring the relationship between EQ-5D, DLQI and PASI
123
Journal : Large 10198 Dispatch : 2-5-2014 Pages : 9
Article No. : 600
h LE h TYPESET
MS Code : Supplement14_Paper12 h CP h DISK4 4
R
E
V
IS
E
D
PR
O
O
F
499 In the multivariate approach of Norlin et al. [8], in
500 addition to DLQI (global score or single items) gender and
501 age were found to be predictors of EQ-5D. Their model
502 could explain 32 % of the variance of EQ-5D.
503 Blome et al. [9] implemented a stepwise linear regres-
504 sion on EQ-5D as well as on EQ-5D VAS with powers of
505 explanation of 27.9 and 31.3 %. Age, presence of active
506 arthritis and concomitant diseases predicted both target
507 variables. Gender, psoriasis duration, and nail involvement
508 were also described as predictors of EQ-5D. Compared to
509 our model, gender, psoriatic arthritis, and disease duration
510 are common predictors. The regression coefficients of
511 DLQI are higher in both the bivariate and the multivariate
512 function of Blome et al., than in ours [9].
513 It seems that gender is the only variable that was found
514 as a predictor in the two referred multivariate mapping
515 functions and also in our model [8, 9]. A literature review
516 on quality of life in psoriasis patients points out that there is
517 no association between gender and HRQOL in psoriasis
518 [2]. However, a few authors have described higher HRQOL
519 impairment in female patients, possibly caused by stig-
520 matisation and additional mental disorders [17, 27]. Lesuis
521 et al. [28] also indicated that men more often had high
522 PASI scores and women more often had high DLQI scores.
523 In our study we could not justify significant difference
524 neither in DLQI nor in PASI index, nonetheless, median
525 EQ-5D in female patients was significantly worse than in
526 males (0.67 vs 0.8, p \ 0.001).
527 Mapping EQ VAS, we observed that self-assessed dis-
528 ease severity VAS overwhelmed DLQI as a possible pre-
529 dictor, and hence, confirmed the importance of self-
530 assessed disease severity as an outcome measure, as earlier
531 also highlighted by Hjortsberg et al. [11].
532 To summarise, the three cited bivariate models can
533 predict a greater proportion of the variance of EQ-5D or
534 EQ VAS than our mapping functions. However, our mul-
535 tiple linear regression algorithm can predict 48.8 % of EQ-
536 5D scores, which is more accurate than in any previously
537 published models.
538 Finally, a number of important limitations need to be
539 considered. To our knowledge, HRQOL median values of
540 our sample are reflecting better health states than in other
541 previous cross-sectional surveys. This might be the result
542 of the biological treatment received by about half of our
543 patients and also due to the treatment institutions, which
544 were two university clinics considered to offer higher
545 quality of care. Additionally, several limitations of map-
546 ping should be noted. Sample size was relatively small,
547 only the ordinary least squares method was applied and no
548 cross-validation was conducted. A recently published study
549 suggests that the ordinary least squares method systemati-
550 cally underestimates mapping from disease-specific mea-
551 sures, like DLQI to generic measures such as EQ-5D [29].
552Consequently, the developed mapping algorithm is proba-
553bly not transferable to all Hungarian psoriasis patients,
554merely to subgroups of patients.
555A broader survey including more variables not investi-
556gated in this study (e.g., time on biological treatment,
557comorbidities and concomitant medications, mental health,
558body image, coping mechanisms) is needed to reduce the
559uncertainties around the model and to determine the still
560unexplained 51.2 % of EQ-5D. A detailed analysis in terms
561of the individual five dimensions of EQ-5D and of each
562DLQI questions or items might as well improve the pre-
563dictive power of mapping [30].
564This current study confirms previous findings about
565correlations between EQ-5D, EQ VAS, DLQI, and PASI.
566We provided the first evidence that visible psoriatic
567lesions have a significant impact on HRQOL measured
568not only with DLQI, but also with EQ-5D, compared to
569non-visible skin lesions. We revealed new possible pre-
570dictors of HRQOL, such as clinical types and localisa-
571tion of psoriasis, and the necessity of home help in
572patients with moderate to severe psoriasis. In clinical
573trials, when direct utility outcomes are not available, our
574mapping functions can contribute to the valuation of
575utilities. Notwithstanding the limitations listed above,
576predictors tested in a multivariate approach explained a
577higher proportion of variance of EQ-5D in psoriasis than
578any other models before.
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